Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000233592 | SCV000289943 | pathogenic | Spastic paraplegia | 2016-02-11 | criteria provided, single submitter | clinical testing | This sequence change affects a donor splice site in intron 4 of the VAMP1 gene. It is expected to disrupt mRNA splicing and likely results in an absent or disrupted protein product. This variant has been reported in many (>10) individuals affected with spastic ataxia. In addition, it has been shown to segregate with disease in 4 large families with origins in Newfoundland, Cananda (PMID: 22958904). Experimental studies have shown that this intronic change leads to aberrant splicing of intron 4, which is predicted to lead to a truncated protein product relative to the major VAMP1 neuronal isoform (PMID: 22958904). In summary, this variant has been reported to segregate with disease in affected families and to alter mRNA splicing in functional studies. For these reasons, this change has been classified as Pathogenic. |
Gene |
RCV000255544 | SCV000322101 | pathogenic | not provided | 2025-01-22 | criteria provided, single submitter | clinical testing | Published functional studies demonstrate that this variant affects a critical donor site for the splicing of VAMP1 isoforms and results in an in-frame addition of 33 amino acids (PMID: 22958904); Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports a deleterious effect on splicing; This variant is associated with the following publications: (PMID: 27957547, 11774073, 22958904, 38355957) |
Athena Diagnostics | RCV000255544 | SCV000844856 | pathogenic | not provided | 2017-11-30 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV005008203 | SCV005629613 | pathogenic | Spastic ataxia 1; Myasthenic syndrome, congenital, 25, presynaptic | 2024-01-12 | criteria provided, single submitter | clinical testing | |
OMIM | RCV000128446 | SCV000172127 | pathogenic | Spastic ataxia 1 | 2012-09-07 | no assertion criteria provided | literature only |